Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of HQK-1001 administered
daily for 8 weeks in subjects with beta thalassemia intermedia